Wockhardt Ltd

โ‚น 1,395 0.54%
14 Jan
๐Ÿ”— Website | BSE: 532300 | NSE: WOCKPHARMA
22,669
1,395
1,870
161
178
0.00
4.40
-0.53

ABOUT

Wockhardt is a global pharmaceutical and biotechnology organization engaged in manufacturing finished dosage formulations, injectables, biopharmaceuticals, orals and topicals (creams and ointments).[1]

Stock Analysis

Description

  • Wockhardt Limited is a global pharmaceutical and biotechnology organization focused on manufacturing finished dosage formulations, injectables, biopharmaceuticals, orals, and topicals, strategically transitioning towards innovation-led growth.

Key Growth Triggers

  • Strategic pivot to innovation-led growth, particularly in novel antibiotics and biosimilars, evidenced by the US FDA acceptance of the NDA for Zaynichยฎ (WCK 5222) and EMA's accelerated assessment for the same drug.
  • Focus on developing products for diabetes and anti-infectives, with successful Phase 3 results for Miqnafยฎ published.
  • Incorporation of step-down subsidiaries in Switzerland and USA to facilitate product channeling in key markets.

Order Book

  • Currently no data available for Order Book.

Key Red Flags

  • The company's consolidated financial performance was impacted by a โ‚น97 crore goodwill impairment charge related to the strategic exit from the US generic pharmaceutical business.
  • A Tax Demand Order for FY20 amounting to โ‚น90.23 lakh was received, although the company states it has no material impact and plans to appeal.

Key Dates To Watch

  • Progress on regulatory approvals for Zaynichยฎ in the US and WCK 5222 in Europe.
  • Future financial results announcements to track the ongoing impact of the strategic shift and performance of new products.

Peer Comparison

S.No.NameCurrent Price (Rs.)Price to EarningMarket Capitalization (Rs.Cr.)Dividend yield (%)Net Profit latest quarter (Rs.Cr.)YOY Quarterly profit growth (%)Sales latest quarter (Rs.Cr.)YOY Quarterly sales growth (%)Return on capital employed (%)Sales (Rs.Cr.)OPM (%)Profit after tax (Rs.Cr.)Profit after tax latest quarter (Rs.Cr.)Price to book valueReturn on assets (%)Debt to equity
1.Sun Pharma.Inds.1700.7035.35408054.900.943124.952.5614478.318.9320.2154964.0130.1211543.963117.955.2412.970.07
2.Divi's Lab.6355.5067.89168718.560.47689.0035.102715.0016.1220.4410029.0032.372485.00689.0010.9513.530.01
3.Torrent Pharma.4003.7062.54135503.400.80591.0032.493302.0014.3027.0512248.0032.602166.53600.1716.0413.260.33
4.Cipla1434.5021.30115874.780.911353.373.737589.447.6422.7228349.5725.405441.141351.173.5214.720.01
5.Lupin2195.9023.19100308.450.551484.8373.347047.5124.2321.3024750.6927.254324.631477.925.1112.410.32
6.Dr Reddy's Labs1186.5017.1699028.890.671336.807.288828.309.8322.6934310.0024.645772.201347.102.7512.950.16
7.Mankind Pharma2244.4052.9992649.970.04520.18-22.003697.1620.7715.9813545.6724.121748.55511.516.068.890.55
8.Wockhardt1395.10160.7822669.280.0054.00250.00380.002.704.401473.0027.97141.0054.007.85-0.230.76

Quarterly Results

Figures in Cr.

Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
Sales
258282291251260288355352370325355413380
YOY Sales Growth %
-16.77%-8.74%-38.61%4.15%0.78%2.13%21.99%40.24%42.31%12.85%0%17.33%2.7%
Expenses
247256321256270263401272321263249282267
Material Cost %
37.21%37.59%39.18%41.04%40.38%40.97%38.03%36.08%37.3%26.46%23.94%27.36%18.68%
Employee Cost %
23.64%22.34%17.87%25.1%24.23%20.49%17.46%17.61%17.57%21.85%18.03%16.46%23.16%
Operating Profit
1126-30-5-1025-46804962106131113
OPM %
4%9%-10%-2%-4%9%-13%23%13%19%30%32%30%
Other Income
-2118-156-8652427116142530
Exceptional items
-500-185-14000000000
Other income normal
2918296652427116142530
Interest
58525858596159585348404144
Depreciation
47474544444345434342404645
Profit before tax
-115-55-289-115-107-74-1266-36-22406954
Tax %
-35%0%3%0%0%0%0%0%0%0%0%0%0%
Net Profit
-75-55-299-115-107-74-1266-36-22406954
EPS in Rs
-5.21-3.82-20.75-7.98-7.43-5.14-8.210.39-2.35-1.352.464.253.32

Profit & Loss

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales
1,8051,8872,2172,2982,4771,5578909871,3721,0721,1541,4021,473
Sales Growth %
โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”
Expenses
1,7801,8792,0912,1532,1541,6191,0231,1251,1501,0021,1901,1021,061
Material Cost %
โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”
Raw material cost
โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”
Change in inventory
โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”
Manufacturing Cost %
โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”
Employee Cost %
โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”
Other Cost %
โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”
Operating Profit
257126145323-62-133-13822270-36300412
OPM %
1%0%6%6%13%-4%-15%-14%16%7%-3%21%28%
Other Income
319465622485712613888438-168275575
Exceptional items
โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”
Other income normal
โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”
Interest
3419108169170171220200273229237199173
Depreciation
9610399106106120173184171186176168173
Profit before tax
215350-20119104-227-389362-184-513-422-12141
Tax %
8%5%-143%-15%34%-64%-41%-64%-24%-9%0%0%โ€”
Net Profit
199332813769-82-231593-140-466-422-12141
Exceptional items AT
โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”
Profit excl Excep
โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”
Profit for PE
โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”
Profit for EPS
โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”
EPS in Rs
13.9223.190.589.544.77-5.69-16.0541.18-9.72-32.34-27.51-0.748.68
Dividend Payout %
55%66%0%81%0%0%0%0%0%0%0%0%โ€”

Balance Sheet

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital
55555555555555557272778181
Reserves
8821,0161,1131,1641,2391,1719391,5512,1401,6811,7192,6822,805
Borrowings
4821,1381,9842,1201,7731,8852,3702,0782,0242,0132,1361,7962,205
Long term Borrowings
75681,4331,283758942520259146128919371,382
Short term Borrowings
1742705506624375628811,3541,4441,608899590581
Lease Liabilities
โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”
Other Borrowings
22217557814747600000โ€”
Other Liabilities
1,9721,9391,4311,2301,3181,4261,3951,2111,562966936849851
Trade Payables
331344332346446619524405582557580476477
Advance from Customers
7001,27221920680646151862674109199โ€”
Other liability items
941323880677792744809288354335247174374
Total Liabilities
3,3914,1494,5844,5694,3864,5384,7604,8955,7984,7324,8685,4085,942
Fixed Assets
1,0331,0051,4021,4651,4231,6142,0441,6841,8281,6251,4491,2762,559
Land
7171198198198198192103103545050โ€”
Building
188207240267273370910861944943939921โ€”
Plant Machinery
1,1441,1951,5131,6371,6721,8731,9201,7471,9641,9791,9721,973โ€”
Equipments
8910111316141314141414โ€”
Furniture & fittings
โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”
Vehicles
667778888778โ€”
Intangible Assets
1221221221221221221222202202202262261,376
Other fixed assets
263339455052555758616161โ€”
Gross Block
1,6201,7092,2062,3712,4282,7403,3153,1053,4123,3833,3743,358โ€”
Accumulated Depreciation
5877048049061,0061,1261,2711,4211,5841,7581,9252,082โ€”
CWIP
5827926646656533813057168258238331,260100
Investments
308297297297297297297297297297297719993
Other Assets
1,4692,0542,2212,1422,0132,2452,1132,1982,8481,9872,2892,1532,290
Inventories
484524535535377370315348387363321426501
Trade receivables
2462102713438001,0059409551,292551566612731
Receivables under 6m
2171922924078661,0721,029382443598332340โ€”
Receivables over 6m
73644300006599250289333โ€”
Prow for Doubtful
โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”
Cash Equivalents
8667883566025322615713820737486113110
Loans & Advances
โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”
Other Assets items
โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”
Total Assets
3,3914,1494,5844,5694,3864,5384,7604,8955,7984,7324,8685,4085,942

Cash Flows

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity
131-53-363-23511958222-563-9371188-14
Profit from operations
112551461543559818-134226-8072309
Receivables
-7210-77-78-461-1918813-298759-15-42
Inventory
43-40-122158329-30-392428-105
Payables
-14650-922102167-97-136165000
Loans Advances
-501200000-52-128-5871-273
Other WC items
278-50-407-310-246184-11360-5693270
Working capital changes
54-18-505-365-226-15204-318-240156116-350
Direct taxes
-35-91-4-25-10-24-0-111-79-5027
Cash from Investing Activity
-25203-1,015369451120-161,014-244-3-75-900
Fixed assets purchased
-282-305-281-162-45-26-22-526-254-47-88-504
Fixed assets sold
39021201139010
Investments purchased
00000000000-404
Investments sold
โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”
Interest received
10837643296142233
Redeemp Cnce of Shares
โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”
Acquisition of companies
โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”
Other investing items
4857-771294463135-01,5257310-5
Cash from Financing Activity
-188425764-133-524-69-274-480430-236346486
Redemption of debentures
โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”
Proceeds from borrowings
1166583612043232124391,397395477430
Repayment of borrowings
-2-2-2-2-399-239-268-340-1,725-368-382-763
Interest paid fin
-33-19-70-141-128-132-148-152-149-181-134-88
Dividends paid
-164-220-0-110-0-00-1-2000
Financial liabilities
000000-70-72-75-79-82-75
Other financing items
00000-210-354-1-3-1-1
Net Cash Flow
-81575-614146109-69-2993-168459-428

Ratios

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days
50414554118236385353344188179159
Inventory Days
221240216206141195367305297330254357
Days Payable
151158134133167325611355446507459398
Cash Conversion Cycle
1201231261279210514130319411-26117
Working Capital Days
-91-223-18-73-55-52-351-334-231-404-223-7
ROCE %
18%20%3%9%9%-2%-8%-8%2%-1%-4%4%

Shareholding Pattern

Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
Promoters
60.36%59.31%58.4%55.14%54.93%51.6%51.99%51.99%49.09%49.09%49.09%49.09%
Ananke Trustee Company Private Limited
2.892.892.892.542.542.392.482.482.352.352.352.35
Ananke Trustee Company Private Limited - 2
0.190.190.190.190.190.180.180.180.170.170.170.17
Callirhoe Trustee Company Private Limited
2.892.892.891.851.851.732.032.031.921.921.921.92
Callirhoe Trustee Company Private Limited - 2
0.650.650.650.650.650.610.610.610.580.580.580.58
Dartmour Holdings Private Limited
000000000000
Habil F Khorakiwala
0.410.410.410.410.410.390.390.390.370.370.370.37
Huzaifa Habil Khorakiwala
0.190.190.190.190.190.180.180.180.170.170.170.17
Khorakiwala Holdings and Investments Private Limited
000000000000
Miqdad H Khorakiwala
000000000000
Muayyad H Khorakiwala
โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”0000
Murtaza Habil Khorakiwala
0.20.20.20.20.20.190.190.190.180.180.180.18
Nafisa Habil Khorakiwala
000000000000
Palanpur Holdings and Investments Private Limited
000000000000
Pasithee Trustee Company Private Limited
3.073.073.073.073.072.882.882.882.722.722.722.72
Pasithee Trustee Company Private Limited - 2
0.450.450.450.450.450.420.420.420.40.40.40.4
Themisto Trustee Company Private Limited
49.3248.2747.3645.4945.2842.5342.5342.5340.1640.1540.1540.15
Themisto Trustee Company Private Limited - 2
0.090.090.090.090.090.080.080.080.080.080.080.08
Zahabiya Khorakiwala
000000000000
FIIs
2.87%2.78%2.6%3.03%4.18%5.49%5.94%6.7%6.54%6.82%7.29%7.1%
DIIs
0.22%0.22%0.18%0.21%0.3%4.82%4.45%5.08%9.82%10.58%11%11%
3p India Equity Fund 1
โ€”โ€”โ€”โ€”โ€”โ€”โ€”1.471.391.621.671.58
Hdfc Large And Mid Cap Fund
โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”1.121.191.19โ€”
Hsbc Small Cap Fund
โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”1.011.191.18
Icici Prudential Elss Tax Saver Fund
โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”1.06โ€”โ€”โ€”
Icici Prudential Equity & Debt Fund
โ€”โ€”โ€”โ€”โ€”1.261.271.27โ€”โ€”โ€”โ€”
Tata Mutual Fund - Tata Small Cap Fund
โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”1.091.642.122.16
Government
0%0%0%0%0%0.01%0.01%0.02%0.02%0.02%0.02%0.02%
Public
36.55%37.7%38.83%41.62%40.59%38.06%37.62%36.21%34.54%33.5%32.6%32.79%
Others
โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”
No. of Shareholders
1,84,9081,82,4931,78,9151,72,9891,61,8131,46,1381,40,3911,38,1421,42,7101,41,7991,46,9181,37,946

News & Updates

BSE Announcements

Direct from BSE filings, AI summarised

Wockhardt Limited Achieves Milestone US FDA NDA Acceptance for Zaynichยฎ, Secures Credit Rating Upgrade to Positive Outlook
8 Jan 2026
Wockhardt Files Marketing Authorisation Application for Novel Antibiotic WCK 5222 with EMA, Securing Accelerated Assessment
7 Jan 2026
Wockhardt Receives 'Excellent' ESG Rating (73) from Independent Agency, Reflecting Strong Sustainability Commitment
1 Jan 2026
Wockhardt Receives 'Excellent' ESG Rating (73) from Independent Agency, Reflecting Strong Sustainability Commitment
1 Jan 2026
Wockhardt Limited Receives 'Strong' ESG Rating of 67.3 from SES ESG Research
31 Dec 2025

Other Websites

External media mentions

Jefferies Forecasts Weak Pharma H1 2026; Names Top Stock Picks
8 Jan 2026
Wockhardt Seeks EU Approval for Novel Antibiotic WCK 5222
7 Jan 2026
Wockhardt Shares Jump 4% on EU Regulatory Filing for Novel Antibiotic WCK 5222
7 Jan 2026
Pharma Stocks Surge on Brokerage Optimism, CRDMO Growth Outlook
6 Jan 2026
Indian Pharma's Innovation Payoff: Glenmark, Wockhardt Lead Global Push
6 Jan 2026

News Articles

Editorial & research coverage

Jefferies Forecasts Weak Pharma H1 2026; Names Top Stock Picks
8 Jan 2026
Wockhardt Seeks EU Approval for Novel Antibiotic WCK 5222
7 Jan 2026
Pharma Stocks Surge on Brokerage Optimism, CRDMO Growth Outlook
6 Jan 2026
Indian Pharma's Innovation Payoff: Glenmark, Wockhardt Lead Global Push
6 Jan 2026
US Senate Sparks Pharma Surge: Indian Stocks Soar on Biosecure Act News!
19 Dec 2025

Documents

Announcements

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
8 Jan - Depositories and Participants) Regulations, 2018, please find enclosed the Certificate received from MUFG Intime India Private Limited, Registrar and Share Transfer Agent of the Company โ€ฆ
Announcement under Regulation 30 (LODR)-Press Release / Media Release
7 Jan - Filed EMA MAA for WCK 5222 on 5 Jan 2026; EMA granted accelerated assessment.
Intimation Under Regulation 30 Of The SEBI (LODR) Regulations, 2015 - ESG Ratings
1 Jan - ESG Risk Assessments assigned Wockhardt 73 (Excellent) for 2025; rating independent, based on public disclosures.
Intimation Under Regulation 30 Of The SEBI (LODR) Regulations, 2015 - ESG Ratings
31 Dec - SES ESG Research assigned ESG rating 67.3 for FY2024-25; company not engaged.
Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order
31 Dec - GST demand โ‚น90.23 lakh (incl. โ‚น28.08 lakh penalty) dated 26-Dec-2025; company to appeal.

Annual Reports

Credit Ratings

Rating update
26 Aug 2025 from icra
Rating update
30 Aug 2024 from care
Rating update
3 Jul 2024 from fitch
Rating update
15 May 2024 from icra
Rating update
10 Oct 2023 from fitch
Rating update
18 Sep 2023 from fitch

Concalls

Jun 2025
Jun 2025
PPT
Feb 2025
PPT
Oct 2024
PPT
Feb 2024
PPT
Feb 2023
Mar 2022
PPT